339 related articles for article (PubMed ID: 15583654)
21. The origins of new drugs.
Kneller R
Nat Biotechnol; 2005 May; 23(5):529-30. PubMed ID: 15877061
[No Abstract] [Full Text] [Related]
22. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
23. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
24. Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.
Segreti AC; Leung HM; Koch GG; Davis RL; Mohberg NR; Peace KE
J Biopharm Stat; 2001 Nov; 11(4):347-72. PubMed ID: 12018784
[TBL] [Abstract][Full Text] [Related]
25. Security market reaction to FDA fast track designations.
Anderson CW; Zhang Y
J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
[TBL] [Abstract][Full Text] [Related]
26. Drug regulation 2056.
Bezold C; Peck J
Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091
[No Abstract] [Full Text] [Related]
27. Is the drought over for pharming?
Kaiser J
Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771
[No Abstract] [Full Text] [Related]
28. Macro trends in pharmaceutical innovation.
Cohen FJ
Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
[TBL] [Abstract][Full Text] [Related]
29. Big Pharma's Commedia.
Steele FR
Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
[No Abstract] [Full Text] [Related]
30. Redesigner drugs.
Dove A
Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
[TBL] [Abstract][Full Text] [Related]
31. Oncology's trials.
Booth B; Glassman R; Ma P
Nat Rev Drug Discov; 2003 Aug; 2(8):609-10. PubMed ID: 12908467
[No Abstract] [Full Text] [Related]
32. Mammalian cell cultures for biologics manufacturing.
Kantardjieff A; Zhou W
Adv Biochem Eng Biotechnol; 2014; 139():1-9. PubMed ID: 24258145
[TBL] [Abstract][Full Text] [Related]
33. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
34. Can China bring its own pipeline to the market?
Louët S
Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
[No Abstract] [Full Text] [Related]
35. Current trends in the clinical development of peptide therapeutics.
Saladin PM; Zhang BD; Reichert JM
IDrugs; 2009 Dec; 12(12):779-84. PubMed ID: 19943221
[TBL] [Abstract][Full Text] [Related]
36. New drug approvals for 2002.
Frantz S; Smith A
Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
[No Abstract] [Full Text] [Related]
37. Pharma's year of trouble and strife.
Frantz S
Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
[No Abstract] [Full Text] [Related]
38. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
39. Researchers see a need for speed in EU trial approvals.
Cressey D
Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
[No Abstract] [Full Text] [Related]
40. Tysabri's troubles return.
Hoag H
Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
